News

ELCC 2018 Press Release: Alectinib Provides Longer Symptom Improvement than Crizotinib in ALK-positive Lung Cancer

Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial (1) presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Apr 12 2018 | More

ELCC 2018 Press Release: Further Evidence that Immunotherapy Provides a Long-term Survival Benefit for Lung Cancer Patients

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.

Apr 12 2018 | More

ELCC 2018 Press Release: Coordinating Nurses Can Improve Cancer Patients’ Quality of Life and Satisfaction During Treatment

Investing in the continuity of care for lung cancer patients can bring tremendous benefits in terms of patient satisfaction and quality of life.

Apr 12 2018 | More

REQUEST FOR PROPOSAL: IASLC WCLC Daily Newspaper

The International Association for the Study of Lung Cancer (IASLC) seeks a Vendor to produce a daily “newspaper” during each day of its annual world conference.

Apr 3 2018 | More

IASLC Newsletter - March 2018

Immunotherapy has recently emerged as a new treatment modality in lung cancer, and reactivating immune responses that are silenced by immune checkpoints is an idea that has recently gained a lot of interest.

Read more

ELCC 2018 Press Release: Heine H. Hansen Award Given to Fabrice Barlesi

The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced that the 2018 Heine H. Hansen (HHH) Award will be given to Fabrice Barlesi.

Mar 27 2018 | More

Pages